Sanodyne Therapeutics, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Ryota Sakurai; hereinafter “the Company”) is pleased to announce the completion of its Series Seed financing round through a third-party allotment of shares to JIC Venture Growth Investments and RDiscovery. With this financing, the Company’s cumulative funds raised have reached approximately 800 million Japanese yen.

  As previously announced, the Company has also been selected for the “Strengthening the Drug Discovery Venture Ecosystem Project (11th Round)” (hereinafter “the Project”) by the Japan Agency for Medical Research and Development (AMED). Since both of the underwriters in this round are AMED-certified VCs, the Company will utilize the newly raised funds in conjunction with the Project to further accelerate the development of its lead compound, SNT-001.

[About Sanodyne Therapeutics, Inc.]

Address: 7F Nihonbashi Muromachi Mitsui Tower, 3-2-1 Nihonbashi Muromachi, Chuo-ku, Tokyo

Representative: Ryota Sakurai, Representative Director & CEO

Established: April 18, 2025

[About the AMED Strengthening the Drug Discovery Venture Ecosystem Project]

For more details on the Project, please refer to the following:

・Call for Proposals for the Strengthening the Drug Discovery Venture Ecosystem Project (Drug Discovery Venture Open Call) (11th Round)

https://www.amed.go.jp/koubo/03008/01/C_00002.html

[Contact Information]

https://sanodyne.com/contact